Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Reappraisal of GIP pharmacology for metabolic diseases.
Trends Mol. Med. 22, 359-376 (2016)
Glucagon-like peptide-1 (GLP-1) analogs are considered the best current medicines for type 2 diabetes (T2D) and obesity due to their actions in lowering blood glucose and body weight. Despite similarities to GLP-1, glucose-dependent insulinotropic polypeptide (GIP) has not been extensively pursued as a medical treatment for T2D. This is largely based on observations of diminished responses of GIP to lower blood glucose in select patients, as well as evidence from rodent knockout models implying that GIP promotes obesity. These findings have prompted the belief in some, that inhibiting GIP action might be beneficial for metabolic diseases. However, a growing body of new evidence - including data based on refined genetically modified models and improved pharmacological agents - suggests a paradigm shift on how the GIP system should be manipulated for metabolic benefits.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
9.292
2.399
67
91
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Review
Keywords
Dependent Insulinotropic Polypeptide; Gastric-inhibitory Polypeptide; Glucagon-like Peptide-1; High-fat Diet; Pancreatic Beta-cells; Improves Glucose-tolerance; Type-2 Diabetes-mellitus; Receptor Knockout Mice; Rat Adipose-tissue; Blood-glucose
Language
Publication Year
2016
HGF-reported in Year
2016
ISSN (print) / ISBN
1471-4914
e-ISSN
1471-499X
Journal
Trends in Molecular Medicine
Quellenangaben
Volume: 22,
Issue: 5,
Pages: 359-376
Publisher
Elsevier
Publishing Place
Oxford
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes and Obesity (IDO)
POF-Topic(s)
30201 - Metabolic Health
90000 - German Center for Diabetes Research
90000 - German Center for Diabetes Research
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-502200-001
G-501900-221
G-501900-221
WOS ID
WOS:000375814100004
Scopus ID
84962046497
PubMed ID
27038883
Erfassungsdatum
2016-04-15